Sarepta Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $362,931 | $413,464 | $396,781 | $331,817 |
Gross Profit | 309,667 | 362,905 | 352,605 | 294,791 |
EBITDA | 12,030 | 64,458 | -28,460 | 12,483 |
EBIT | -701 | 51,762 | -43,691 | -2,270 |
Net Income | 6,460 | 36,119 | 45,655 | -40,937 |
Net Change In Cash | 362,931 | 413,464 | 396,781 | 331,817 |
Free Cash Flow | -14,225 | -284,520 | -73,696 | -155,618 |
Cash | 383,622 | 427,290 | 428,430 | 541,932 |
Basic Shares | 94,618 | 99,114 | 105,594 | 88,889 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,243,336 | $933,013 | $701,887 | $540,099 |
Gross Profit | 1,092,993 | 793,024 | 604,838 | 476,717 |
EBITDA | -267,824 | -473,535 | -412,118 | -529,276 |
EBIT | -326,716 | -528,134 | -461,460 | -569,015 |
Net Income | -535,977 | -703,488 | -418,780 | -554,128 |
Net Change In Cash | 1,243,336 | 933,013 | 701,887 | 540,099 |
Cost of Revenue | 613,810 | 668,068 | ||
Free Cash Flow | -588,338 | -356,170 | -481,662 | 25,264 |
Cash | 428,430 | 966,777 | 2,115,869 | 1,502,648 |
Basic Shares | 92,398 | 87,559 | 81,262 | 77,956 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | $0.07 |
2024-03-31 | $0.37 |
2023-12-31 | $0.47 |
2023-09-30 | -$0.46 |
